Fludrocortisone

證據等級: L5

預測適應症: 10 個

Fludrocortisone: From Adrenal Insufficiency to Eye Disease

One-Sentence Summary

Fludrocortisone is a potent synthetic mineralocorticoid, established for treating adrenal insufficiency (Addison's disease) and salt-wasting adrenogenital syndrome. The TxGNN model's highest-scoring prediction is primary cutaneous T-cell lymphoma (99.58%), but this lacks clinical evidence (L5, Hold); the most evidence-supported new indication is Eye Disease — specifically geographic atrophy secondary to age-related macular degeneration — with 1 Phase 1B study identified in the literature and 20 publications supporting this direction (L3, Proceed with Guardrails).

Quick Overview

Item	Content
Original Indication	Adrenal insufficiency (Addison's disease); salt-wasting adrenogenital syndrome
Predicted New Indication	Eye Disease (geographic atrophy / age-related macular degeneration)
TxGNN Prediction Score	99.14%
Evidence Level	L3
Singapore Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Fludrocortisone is a synthetic adrenocorticosteroid with markedly potent mineralocorticoid activity (approximately 125 times stronger than cortisol) and moderate glucocorticoid activity. While it is primarily used to replace aldosterone in adrenal insufficiency, the mineralocorticoid receptor (MR) is constitutively expressed throughout the eye — in retinal Müller cells, retinal pigment epithelium (RPE) cells, and ganglion cells. Activation of these receptors can modulate oxidative stress responses, suppress pro-inflammatory cytokines implicated in geographic atrophy pathogenesis (such as IL-1β and complement cascade components), and promote cell survival signaling pathways. The current lack of MOA documentation in the Evidence Pack is a recognized data gap, but this mechanistic rationale is well-established in the experimental literature.

A 2021 preclinical study (PMID 34509498) directly demonstrated that fludrocortisone exerts anti-inflammatory and neuroprotective effects in retinal degeneration models, specifically suppressing Müller cell-mediated cytokine expression under inflammatory challenge — the core pathogenic mechanism of geographic atrophy. This preclinical rationale led to a Phase 1B clinical trial (PMID 36161841, 2022) testing intravitreal fludrocortisone acetate (IVT-FCA) at 1 mg/0.1 mL and 2 mg/0.1 mL in geographic atrophy patients, validating the repurposing hypothesis at an early clinical stage. Separately, some glaucoma clinicians already use fludrocortisone (combined with salt intake) to stabilize nocturnal blood pressure dips in normal-tension glaucoma, leveraging its mineralocorticoid activity to maintain optic nerve perfusion pressure (PMID 17998043; PMID 23430676).

⚠️ A critical counter-signal must be noted: systemic corticosteroids — including mineralocorticoids — can elevate intraocular pressure (IOP), and fludrocortisone's effects on aqueous humor outflow resistance have been documented since 1964 (PMID 14211917). Furthermore, systemic fludrocortisone can cause sodium and fluid retention sufficient to raise intracranial pressure, with optic papillitis documented as a direct iatrogenic complication (PMID 3263626). These risks make intravitreal delivery — as explored in the Phase 1B trial — the strongly preferred route over systemic administration for any ophthalmic indication.

Clinical Trial Evidence

Currently no related clinical trials registered.

Important note: A Phase 1B study (PMID 36161841, 2022) evaluating single-dose intravitreal fludrocortisone acetate in geographic atrophy patients was identified through the literature search but was not captured in the ClinicalTrials.gov registry query. This trial represents the primary source of early clinical safety evidence and should be tracked as a priority.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
36161841	2022	Phase 1B Clinical Trial	BMJ Open Ophthalmology	Safety and tolerability of single-dose intravitreal fludrocortisone acetate at 1 mg and 2 mg/0.1 mL in geographic atrophy secondary to AMD — primary safety evaluation
34509498	2021	Preclinical Study	Experimental Eye Research	Fludrocortisone demonstrates anti-inflammatory and neuroprotective properties in retinal degeneration; suppresses Müller cell-mediated cytokine expression under inflammatory challenge
17998043	2007	Review	Survey of Ophthalmology	Fludrocortisone (with salt intake) cited among emerging glaucoma therapies beyond IOP reduction; used to prevent nocturnal blood pressure dips that may drive progressive optic nerve damage
23430676	2013	Review	Klin Monatsbl Augenheilkunde	Confirms fludrocortisone use in vascular-dysregulation glaucoma to stabilize nocturnal ocular perfusion pressure; provides mechanistic framework for MR-targeted ophthalmic therapy
14211917	1964	Experimental Study	Experimental Eye Research	Foundational study on fludrocortisone's effects on IOP and aqueous humor outflow resistance — key safety pharmacodynamics data for ocular use
12770979	2003	Observational Study	British Journal of Ophthalmology	Impact of smoking on thyroid-associated ophthalmopathy treatment — illustrates corticosteroid sensitivity in ocular inflammatory disease relevant to this drug class
17191197	2006	Case report	European Journal of Ophthalmology	Limbal stem cell deficiency in autoimmune polyendocrinopathy — ocular surface complications in patients on long-term mineralocorticoid replacement therapy

Singapore Market Information

Fludrocortisone is currently not registered or marketed in Singapore. No HSA-approved product records are available (0 licenses). A de novo regulatory submission pathway would be required.

Safety Considerations

Formal package insert warnings and contraindications were not available in this Evidence Pack (data gap). Based on pharmacological evidence identified in the literature:

⚠️ Intraocular Pressure Elevation: Corticosteroids, including mineralocorticoids, can increase IOP and precipitate steroid-induced glaucoma. Fludrocortisone's effects on aqueous humor outflow resistance are documented (PMID 14211917). Mandatory IOP monitoring is required for any ophthalmic use; the glaucoma signal makes this drug unsuitable as a systemic agent for eye disease.
⚠️ Adverse Effect Signal — Optic Papillitis: Systemic fludrocortisone causes sodium and fluid retention that can elevate intracranial pressure. A 1988 case report (PMID 3263626) documents recurrent iatrogenic benign intracranial hypertension — with optic papillitis as a direct complication — in a pediatric patient receiving fludrocortisone for congenital adrenogenital syndrome. This adverse effect signal strongly argues for intravitreal over systemic delivery in ophthalmic indications and represents a contraindication signal for neurological/intracranial pressure applications.
Sodium/Fluid Retention (Systemic): Potent mineralocorticoid activity drives sodium retention, potentially causing hypertension, dependent edema, and hypokalemia. These systemic risks are substantially mitigated by intravitreal delivery.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Fludrocortisone's repurposing for eye disease — specifically geographic atrophy secondary to AMD — is supported by an established mechanistic rationale (MR expression in retinal cells), preclinical neuroprotective evidence (2021), and a completed Phase 1B clinical trial (2022). Intravitreal delivery mitigates systemic mineralocorticoid risks, though IOP monitoring remains mandatory. The drug is unregistered in Singapore and requires a full regulatory pathway.

To proceed, the following is needed:

Obtain full Phase 1B trial results (PMID 36161841) to confirm safety and tolerability outcomes in geographic atrophy patients
Complete MOA documentation via DrugBank API (DG002) to enable formal mechanism-of-action analysis
Identify any ClinicalTrials.gov registration number for the Phase 1B study
Design Phase 2 efficacy trial with primary endpoints (geographic atrophy lesion growth rate, best-corrected visual acuity)
Establish a mandatory IOP monitoring and management protocol for all ophthalmic studies
Assess Singapore HSA regulatory pathway requirements for this unregistered compound
All other top-10 TxGNN predictions (primary cutaneous T-cell lymphoma, dermoid cysts, orbital region disease, exostosis, granulomatous slack skin disease) are rated Hold — clinical or mechanistic evidence is absent, and several high TxGNN scores likely reflect non-specific graph traversal artifacts rather than true pharmacological relevance
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.